Lv71
4050 积分 2021-02-08 加入
Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer
3小时前
求助中
Wishing for a No-Show
10天前
已完结
Mechanisms of adaptive resistance to targeted therapy in RET-aberrant cancers
18天前
已完结
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future
2个月前
已完结
Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods
4个月前
已完结
Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy
5个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
5个月前
已完结
The path to leptomeningeal metastasis
5个月前
已完结
Lung Adenocarcinoma Harboring Concomitant EGFR Mutation and EML4-ALK Fusion That Benefits From Three Kinds of Tyrosine Kinase Inhibitors: A Case Report and Literature Review
6个月前
已完结
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
6个月前
已完结
皖公网安备34019202002308
